A $6.4 billion accord for U.S. drug and medical-device reviews is set to unravel just three months after taking effect as lawmakers squabble over budget cutbacks.
FDA drug review deal set to unravel as fiscal cliff looms
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.